TWI917366B - 親環蛋白抑制劑及其用途 - Google Patents

親環蛋白抑制劑及其用途

Info

Publication number
TWI917366B
TWI917366B TW110110800A TW110110800A TWI917366B TW I917366 B TWI917366 B TW I917366B TW 110110800 A TW110110800 A TW 110110800A TW 110110800 A TW110110800 A TW 110110800A TW I917366 B TWI917366 B TW I917366B
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
formula
organ
acid
Prior art date
Application number
TW110110800A
Other languages
English (en)
Chinese (zh)
Other versions
TW202144379A (zh
Inventor
麥靖邦
漢斯 費
馬法書
邁克 溥
Original Assignee
大陸商睿諾醫療科技(上海)有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商睿諾醫療科技(上海)有限公司 filed Critical 大陸商睿諾醫療科技(上海)有限公司
Publication of TW202144379A publication Critical patent/TW202144379A/zh
Application granted granted Critical
Publication of TWI917366B publication Critical patent/TWI917366B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Analytical Chemistry (AREA)
TW110110800A 2020-03-26 2021-03-25 親環蛋白抑制劑及其用途 TWI917366B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2020081295 2020-03-26
WOPCT/CN2020/081295 2020-03-26
CN2021078391 2021-03-01
WOPCT/CN2021/078391 2021-03-01

Publications (2)

Publication Number Publication Date
TW202144379A TW202144379A (zh) 2021-12-01
TWI917366B true TWI917366B (zh) 2026-03-11

Family

ID=77891510

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110110800A TWI917366B (zh) 2020-03-26 2021-03-25 親環蛋白抑制劑及其用途

Country Status (13)

Country Link
US (3) US12673976B2 (cg-RX-API-DMAC10.html)
EP (2) EP4126905B1 (cg-RX-API-DMAC10.html)
JP (2) JP7761578B2 (cg-RX-API-DMAC10.html)
KR (2) KR20220158760A (cg-RX-API-DMAC10.html)
CN (2) CN115335389A (cg-RX-API-DMAC10.html)
AU (1) AU2021240762A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018929A2 (cg-RX-API-DMAC10.html)
CA (2) CA3172535A1 (cg-RX-API-DMAC10.html)
ES (1) ES3074820T3 (cg-RX-API-DMAC10.html)
IL (1) IL296586B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022011697A (cg-RX-API-DMAC10.html)
TW (1) TWI917366B (cg-RX-API-DMAC10.html)
WO (2) WO2021190601A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111449050A (zh) * 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
GB202207348D0 (en) * 2022-05-19 2022-07-06 Cypralis Ltd Macrocyclic compounds and uses thereof
TW202438040A (zh) * 2023-03-03 2024-10-01 大陸商睿諾醫療科技(上海)有限公司 劑誘導的肝臟病症或疾病的治療和預防
WO2024245384A1 (en) * 2023-06-02 2024-12-05 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof
WO2026119135A1 (en) * 2024-12-03 2026-06-11 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017200984A1 (en) 2016-05-17 2017-11-23 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
WO2019016572A1 (en) 2017-07-21 2019-01-24 Cypralis Ltd CICLOSPORINE ANALOGUES AND USES THEREOF

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
DE69832984T2 (de) * 1997-10-08 2006-09-21 Isotechnika, Inc., Edmonton DEUTERIERtE und undeuterierte CYCLOSPORIN-ANALOGA UND IHRE VERWENDUNG ALS IMMUNMODULIERENDE AGENtIEN
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
US6809077B2 (en) 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
DK1436322T3 (da) 2001-10-19 2008-11-03 Isotechnika Inc Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
JP2007532507A (ja) * 2004-04-08 2007-11-15 ノバルティス アクチエンゲゼルシャフト 脳虚血ならびに脳および脊髄傷害の処置のためのサイクロスポリンの使用
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
CN101068829B (zh) * 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) * 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
MX2011001152A (es) 2008-07-30 2011-06-09 Isotechnika Pharma Inc Moleculas de analogo de ciclosporina no-inmunesupresoras.
RU2492181C2 (ru) 2009-01-30 2013-09-10 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2785978A1 (en) * 2009-12-30 2011-07-07 Scynexis, Inc. Cyclosporine analogues
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
DE102011111991A1 (de) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
US20140213508A1 (en) 2012-10-19 2014-07-31 Scynexis, Inc. Antiviral macrocycles
GB201222455D0 (en) 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
GB201414806D0 (en) 2014-08-20 2014-10-01 Ucl Business Plc Cyclosporin conjugates
CN108025039B (zh) 2015-06-30 2022-07-29 西普拉里斯有限公司 新颖的大环化合物
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
AU2021256222A1 (en) 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017200984A1 (en) 2016-05-17 2017-11-23 S&T Global Inc. Novel cyclosporin derivatives and uses thereof
WO2019016572A1 (en) 2017-07-21 2019-01-24 Cypralis Ltd CICLOSPORINE ANALOGUES AND USES THEREOF

Also Published As

Publication number Publication date
US20240352074A1 (en) 2024-10-24
AU2021240762A1 (en) 2022-10-06
EP4126905C0 (en) 2026-05-13
TW202144379A (zh) 2021-12-01
KR20220158760A (ko) 2022-12-01
MX2022011697A (es) 2022-10-07
KR20220158761A (ko) 2022-12-01
CA3172601A1 (en) 2021-09-30
IL296586B1 (en) 2026-04-01
EP4126904A1 (en) 2023-02-08
US20230174583A1 (en) 2023-06-08
ES3074820T3 (es) 2026-07-23
US12522634B2 (en) 2026-01-13
CN115298199A (zh) 2022-11-04
JP7761578B2 (ja) 2025-10-28
EP4126905B1 (en) 2026-05-13
US12673976B2 (en) 2026-07-07
EP4126905A1 (en) 2023-02-08
WO2021190604A1 (en) 2021-09-30
US20230110497A1 (en) 2023-04-13
JP2023518776A (ja) 2023-05-08
EP4126905A4 (en) 2024-05-29
IL296586A (en) 2022-11-01
IL296586B2 (en) 2026-08-01
JP2023518777A (ja) 2023-05-08
CA3172535A1 (en) 2021-09-30
WO2021190601A1 (en) 2021-09-30
EP4126904A4 (en) 2024-05-29
JP7776435B2 (ja) 2025-11-26
BR112022018929A2 (pt) 2022-12-06
CN115335389A (zh) 2022-11-11
US12060440B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
JP7776435B2 (ja) シクロフィリン阻害剤およびその使用
JP7339296B2 (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
CN115315432A (zh) 亲环蛋白抑制剂及其用途
JP6661533B2 (ja) ミトコンドリアを標的とするジカルボニル捕捉化合物
JP7839090B2 (ja) ネフロトキシン誘発性腎障害の処置及び予防
WO2019222339A1 (en) Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
JP2026048875A (ja) インスリン耐性における使用方法のための治療化合物
AU2017265037B2 (en) Compounds for the treatment of ischemia-reperfusion-related diseases
EA051978B1 (ru) Ингибиторы циклофилина и их применение
JP2016513723A (ja) 化学療法誘発認知障害の処置
US20220017529A1 (en) Novel l-proline sulfonamide derivatives comprising pyrazolo[4,3- e]tetrazolo[4,5-b][1,2,4]triazine system, method of manufacturing thereof, uses thereof and pharmaceutical composition comprising the same
WO2025141294A1 (en) Novel hydrogen sulfide releasing compounds
KR20050039700A (ko) 이식거부 치료용 화합물 및 치료 방법
CN106588775A (zh) 一种吲唑衍生物及其制备方法和应用
Rodríguez et al. on Nephrotoxicity
KR20170110520A (ko) mTOR 억제제 및 N-아세틸시스테인을 포함하는 간섬유화 억제용 조성물
Su et al. Genetic and Pharmacological Inhibition of Nox4 Protects Against Rhabdomyolysis-Induced Acute Kidney Injury Through Suppressing the Endoplasmic Reticulum Stress
EP2601963A1 (en) N-isovaleroyl-l-glutamyl-l-tryptophan as an agent inhibiting the formation of ulcers in the stomach and the duodenum